Prime Minister Narendra Modi announced at the India-Russia Business Forum that the ambitious USD 100 billion bilateral trade goal can be met ahead of the 2030 target. Read the key outcomes.
Hyderabad's Laurus Labs plans aggressive CDMO growth, targeting 50% of revenue in five years. CEO Dr. Satyanarayana Chava reveals strategy focusing on cell & gene therapy and global expansion. Read more.
Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.
Corona Remedies IPO opens Dec 8, 2025, to raise ₹655.37 crore. Check price band, GMP, financials, and key dates for this pharma company's public issue.
Indian stock markets opened strong on December 3, 2025, with Nifty crossing 25,400. Key stocks like TCS and Sun Pharma in focus. Read for full analysis and trading cues.
Wockhardt's share price surged over 6% after the USFDA accepted its New Drug Application for Zaynich, a novel antibiotic. Discover the details and market impact.
Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
November 2025 witnessed 9 IPOs with 12 listings. Groww leads with 58.85% gains while experts warn of investor fatigue and unrealistic valuations. Read full analysis.
Sudeep Pharma shares surged 33.78% in market debut, exceeding expectations. Analysts advise partial profit booking while maintaining long-term optimism. Read expert views on buy/sell strategy.
Sudeep Pharma shares surged 23% in stock market debut today, outperforming grey market expectations. The ₹895-crore IPO was subscribed 93.71 times. Read full analysis.
Sudeep Pharma makes its stock market debut today. With a GMP of ₹121, the IPO is set for 20% listing gains after a blockbuster 93.72 times subscription. Get all the live details.
Sudeep Pharma shares list on BSE and NSE today after 93.72 times subscription. Grey market signals 20% premium debut. Full details on pricing and investor response.
Sudeep Pharma IPO makes Dalal Street debut on November 28. Grey market premium hits ₹100, signaling 15% listing gain. Discover subscription details and key facts.
Bokaro police register FIR against Aryan Singh of New Sun Pharma for illegal codeine syrup trade. 32,000 bottles seized. Read the full investigation details.
Maharashtra's new industrial policy aims to unlock $850 billion in manufacturing and services. State targets $1 trillion economy by 2030, driven by EVs and semiconductors.
Shaily Engineering and Gland Pharma positioned to benefit from India's semaglutide gold rush as patent expiry opens market for generic weight-loss drugs. Discover how these companies are preparing.
Sudeep Pharma IPO allotment finalized today after massive 93.71x subscription. GMP at ₹87 signals 14.67% listing gain. Track your allotment status now!
Sudeep Pharma IPO allotment likely on November 26. Learn how to check allotment status via BSE, NSE, registrar. Strong 93.72x subscription signals investor confidence.
Sudeep Pharma's ₹895 crore IPO witnessed massive demand, subscribed 94 times. QIB portion booked 213x. Shares may list at a 14% premium. Key details inside.
HD Hyundai Heavy Industries secures massive $1.45 billion order for 8 large container ships from Oceania, strengthening India's shipbuilding export capabilities. Read more about this landmark deal.
Sudeep Pharma IPO sees massive 5.09x subscription on Day 2. Grey market premium hits ₹86. Allotment scheduled for November 26. Apply before closing tomorrow!
Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.
OpenAI partners with Foxconn to build $500B AI infrastructure including custom chips and data centers. Bezos's Prometheus challenges xAI in escalating AI talent war. Read more!
OpenAI partners with Foxconn to build $500B AI infrastructure including custom chips and data centers. Bezos's Prometheus challenges xAI in escalating AI talent war. Read more!
Sudeep Pharma's ₹895 crore IPO is fully subscribed. With a GMP of ₹121, investors eye a 20% listing gain. Track all live updates here.
Sudeep Pharma's IPO concludes November 25 after strong第一天 response. Grey market premium hits ₹121, signaling 20% listing gains. Key dates and subscription details revealed.
Aurobindo Pharma's China facility currently faces $1M loss but aims for break-even by Q3-Q4 FY26. CFO outlines growth drivers including Pen-G ramp-up and biosimilar commercialization.
Karnataka Health Minister Dinesh Gundu Rao urges the pharma sector to adhere to regulations, highlighting critical public health and industry credibility issues.